Market Overview

UPDATE: Jefferies Downgrades GlaxoSmithKline to Hold on Margin Expansion Visibility

Share:
Related GSK
EXCLUSIVE: Inovio Plans On Producing Zika Vaccine By Q3 2016, Ready For Phase 1 Study By Q4
Benzinga's M&A Chatter for Thursday January 28, 2015
Are There Any Small Biotechnology Companies With An Answer To The Zika Virus Question? (Seeking Alpha)

Jefferies cut its rating on GlaxoSmithKline (NYSE: GSK) from Buy to Hold on reduced visibility to the company's margin expansion.

Jefferies commented, "Whilst we still see double digit CORE EPS growth for GlaxoSmithKline from 2013E-17E, visibility on margin expansion has been obscured by over-exposure to price pressure and transfer pricing in Europe. The shares have recovered well from their lows since the Q2'12 results and we take this opportunity to cut our rating to Hold from Buy given the limited upside."

GlaxoSmithKline closed at $46.84 on Friday.

Latest Ratings for GSK

DateFirmActionFromTo
Jan 2016Bryan GarnierUpgradesNeutralBuy
Oct 2015Credit SuisseUpgradesUnderperformNeutral
Oct 2015JP MorganUpgradesUnderweightNeutral

View More Analyst Ratings for GSK
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Downgrades Intraday Update Analyst Ratings

 

Related Articles (GSK)

Get Benzinga's Newsletters